Virologic and genetic evaluation of vemurafenib-induced skin cancers

Emi DikaDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, Correspondence[email protected]

Annalisa PatriziDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,

Annalisa AltimariLaboratory of Oncologic and Transplantation Molecular Pathology, University of Bologna, Bologna, Italy,

Michelangelo FiorentinoLaboratory of Oncologic and Transplantation Molecular Pathology, University of Bologna, Bologna, Italy,

Michelangelo La PlacaDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,

Elisa GruppioniLaboratory of Oncologic and Transplantation Molecular Pathology, University of Bologna, Bologna, Italy,

Simona VenturoliDivision of Microbiology, Department of Haematology, Oncology and Laboratory Medicine, Unit of Microbiology, S. Orsola-Malpighi University Hospital, Bologna, Italy, and

Sabina VaccariDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,

Barbara MelottiDivision of Oncology, Department of Haematology, Oncology and Laboratory Medicine, Unit of Microbiology, S. Orsola-Malpighi University Hospital, Bologna, Italy

Bianca Maria PiracciniDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,

Pier Alessandro FantiDermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,

show all

Abstract

We describe the occurrence of a giant squamous cell carcinoma in a patient receiving vemurafenib for the treatment of late melanoma mestastases. Although the development of keratoacanthomas and squamous cell carcinomas (SCC) has been described during vemurafenib therapy, most of the reported cases are treated with surgical excision. In the present case, SCC regressed after drug withdrawal.

Keywords

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Virologic and genetic evaluation of vemurafenib-induced skin cancers

Information for

Open access

Opportunities

Help and information

Virologic and genetic evaluation of vemurafenib-induced skin cancers

Abstract

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature